Evidence map›Paper›PMID 22010140›Full record

ArticleHuman reproduction (Oxford, England)2011

Loss of activity mutations in phospholipase C zeta (PLCζ) abolishes calcium oscillatory ability of human recombinant protein in mouse oocytes.

Junaid Kashir, Celine Jones, Hoi Chang Lee, Katja Rietdorf, Dimitra Nikiforaki, Claire Durrans, Margarida Ruas, Sze Tian Tee, Bjorn Heindryckx, Antony Galione and 4 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Human reproduction (Oxford, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07684339 (Assessing the Correlation Between Phospholipase C Zeta), which is not on this map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
6.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07684339 recruitingnot on this mapstarted 2026, after this paper: background citation

Assessing the Correlation Between Phospholipase C Zeta (PLCZeta) Measurements and Semen Parameters

TypeobservationalSponsorFakih IVF Fertility CenterRan2026 to 2027Enrolled200ConditionsMale Infertility, Male SubfertilityArmsNo Intervention: Observational Cohort
3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Novel mutations inFrontiers in cell and developmental biology · 2023
    Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 3 countries.

Junaid KashirNuffield Department of Obstetrics and Gynaecology, Level 3, Women's Centre, John Radcliffe Hospital, Headington,Oxford OX3 9DU, UK. kevin.coward@obs-gyn.ox.ac.uk
Celine Jones
Hoi Chang Lee
Katja Rietdorf
Dimitra Nikiforaki
Claire Durrans
Margarida Ruas
Sze Tian Tee
Bjorn Heindryckx
Antony Galione
Petra De Sutter
Rafael A Fissore
John Parrington
Kevin Coward
John Radcliffe Hospital · GBUniversity of Oxford · GBGhent University Hospital · BEUniversity of Massachusetts Amherst · US

Funding

LP3R-1 Regulation and Egg ActivationR01HD051872 · NICHD · UNIVERSITY OF MASSACHUSETTS AMHERST · PI FISSORE, RAFAEL ANTONIO · 2007 to 2011
$1.3M
NICHD NIH HHS HD051872
6 · The paper itself

Abstract

backgroundMammalian oocyte activation occurs via a series of intracellular calcium (Ca(2+)) oscillations thought to be induced by a sperm-specific phospholipase C zeta (PLCζ). There is now strong evidence to indicate that certain types of human male infertility are caused by failure of the sperm to activate the oocyte in an appropriate manner. Molecular analysis of the PLCζ gene of a male patient with oocyte activation deficiency has previously identified a point mutation causing a histidine to proline substitution at PLCζ residue 398 (PLCζ(H398P)), leading to abnormal Ca(2+) release profiles and reduced oocyte activation efficiency. METHODS AND

resultsIn the present study, we used HEK293T cells to produce recombinant human wild-type PLCζ (PLCζ(WT)) protein which, upon microinjection into mouse oocytes, induced Ca(2+) oscillations characteristic of oocyte activation. Injection of recombinant PLCζ(H398P) was unable to elicit Ca(2+) oscillations in mouse oocytes. Loss of activity mutations, such as PLCζ(H398P) and an artificially induced frameshift mutation (PLCζ(ΔYC2)) did not affect Ca(2+) release when over-expressed in HEK293T cells, whereas PLCζ(WT) inhibited adenosine triphosphate-activated Ca(2+) release. Confocal imaging of fluorescently tagged PLCζ isoforms in HEK293T cells suggested a cytoplasmic pattern of localization, while quantitative analysis of fluorescence levels showed that PLCζ(WT) > PLCζ(H398P) > PLCζ(ΔYC2), indicating that loss of activity mutations may lead to protein instability. This was further indicated by the low proportion of sperm and the lower levels of total PLCζ immunofluorescence from the patient exhibiting PLCζ(H398P) compared with fertile controls.

conclusionsWe demonstrate, for the first time, the production of active recombinant human PLCζ protein which retained the ability to elicit characteristic Ca(2+) oscillations in mouse oocytes, an ability which was eliminated by an infertility-linked mutation. These findings advance our understanding of PLCζ, and provide a critical step forward in obtaining purified PLCζ protein as a potential therapeutic agent for oocyte activation deficiency.

Indexed as

MutationAdenosine TriphosphateAnimalsCalciumFemaleFluorescent Antibody TechniqueHEK293 CellsHumansMaleMiceOocytesPhosphoinositide Phospholipase CRecombinant ProteinsSpermatozoaSperm-Ovum InteractionsAdenosine TriphosphateCalciumPhosphoinositide Phospholipase CPLCZ1 protein, humanRecombinant Proteins

Identifiers

PMID22010140
PMCPMC3212881
OpenAlexW2097228907

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.